Fig. 6

Nucleoside analogues display increased activity in MB-R cells. A Distribution of 41 different antimetabolites according to their pharmacological classification and target. Each tested compound is represented as a progressively red dot when displaying increased activity against MB-R primary cultures. B Heatmap displaying the differential expression, in MB-R cells, of a subset of genes serving as targets for the antimetabolite drugs tested within the study. C Representative dose–response curves of the most active purine analogues against MB-R primary cultures relative to their MB-S counterparts. D HSA synergy matrixes calculated for the selected purine analogues as in C when combined with VECC in both HuTuP33-R (top panels) and Med-411-R (bottom panels) primary cultures. Compounds have been considered synergistic when HSA ≥ 10, antagonistic when HSA ≤ 10, and non-interactive for 10 > HSA > -10. Relative dose–response matrixes are reported in Supplementary Figure S10